ASHIYA CITY HYOGO 659-0021
14 articles with JCR Pharmaceuticals
EMA grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)
Mar. 30, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that European Medicines Agency (EMA) has granted orphan drug designation to JR-171, an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome).
JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan
JCR Pharmaceuticals Announces Approval of IZCARGO ® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan - First Approved Enzyme Replacement Therapy for MPS II to Penetrate Blood-Brain Barrier via Intravenous Administration, Validating JCR’s J-Brain Cargo ® Technology -
JCR Pharmaceuticals Co., Ltd. announced that it has completed the previously announced acquisition of ArmaGen, Inc., a privately held US biopharmaceutical company headquartered in San Diego, California.
Antares Pharma, Inc. announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring.
JCR Pharmaceuticals And Teijin Limited To Develop Allogeneic Regenerative Medical Product Using Dental Pulp Stem Cells (DPCs)
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
Japanese Biotech JCR Pharmaceuticals Selects Medidata’s Cloud-Based Platform To Power Rare Disease Clinical Research In Japan
Mesoblast Limited Partner JCR Pharmaceuticals Files For Marketing Approval Of The First Allogeneic Stem Cell Product In Japan
Kissei Pharmaceutical Co., Ltd. And JCR Pharmaceuticals Enter Into Joint Research Agreement For JR-013, Recombinant Human Erythropoietin-Based Renal Anemia Agent
Fuji Pharmaceutical Co., Ltd. And, JCR Pharmaceuticals Dissolve Partnership In Renal Anemia Drug Development